Brain scans could predict response to antipsychotic medication

   
   
Brain-2 
15 Aug 2013 12:49:25.330

PA 264/13

Researchers from The University of Nottingham and King’s College London have identified neuroimaging markers in the brain which could help predict whether people with psychosis respond to antipsychotic medications or not.

In approximately half of young people experiencing their first episode of a psychosis (FEP), the symptoms do not improve considerably with the initial medication prescribed, increasing the risk of subsequent episodes and worse outcome. Identifying individuals at greatest risk of not responding to existing medications could help in the search for improved medications, and may eventually help clinicians personalise treatment plans.

In a study published today in JAMA Psychiatry, researchers used structural Magnetic Resonance Imaging (MRI) to scan the brains of 126 individuals — 80 presenting with FEP, and 46 healthy controls. Participants had an MRI scan shortly after their FEP, and another assessment 12 weeks later, to establish whether symptoms had improved following the first treatment with antipsychotic medications

Click here for full story

The researchers examined a particular feature of the brain called “cortical gyrification” — the extent of folding of the cerebral cortex and a marker of how it has developed. They found that the individuals who did not respond to treatment already had a significant reduction in gyrification across multiple brain regions, compared to patients who did respond and to individuals without psychosis. This reduced gyrification was particularly present in brain areas considered important in psychosis, such as the temporal and frontal lobes. Those who responded to treatment were virtually indistinguishable from the healthy controls.

The researchers also investigated whether the differences could be explained by the type of diagnosis of psychosis (eg. with or without affective symptoms, such as depression or elated mood). They found that reduced gyrification predicted non-response to treatment independently of the diagnosis.

Dr Paola Dazzan from King’s College London’s Institute of Psychiatry, and senior author of the paper, says: “Our study provides crucial evidence of a neuroimaging marker that, if validated, could be used early in psychosis to help identify those people less likely to respond to medications. It is possible that the alterations we observed are due to differences in the way the brain has developed early on in people who do not respond to medication compared to those who do.”

She continues: ”There have been few advances in developing novel anti-psychotic drugs over the past 50 years and we still face the same problems with a sub-group of people who do not respond to the drugs we currently use. We could envisage using a marker like this one to identify people who are least likely to respond to existing medications and focus our efforts on developing new medication specifically adapted to this group. In the longer term, if we were able to identify poor responders at the outset, we may be able to formulate personalized treatment plans for that individual patient.”

Dr Lena Palaniyappan from The University of Nottingham adds: “All of us have complex and varying patterns of folding in our brains. For the first time we are showing that the measurement of these variations could potentially guide us in treating psychosis. It is possible that people with specific patterns of brain structure respond better to treatments other than antipsychotics that are currently in use. Clearly, the time is ripe for us to focus on utilising neuroimaging to guide treatment decisions.”

Psychosis is a term used to indicate mental health disorders that present with symptoms like hallucinations (such as hearing voices) or delusions (unshakeable beliefs based on the person’s altered perception of reality, which may not correspond to the way others see the world). Psychotic episodes are present in conditions such as schizophrenia and bipolar disorder.

Approximately 1 in 100 people in England have at least one episode of psychosis throughout their lives. In most cases, psychosis develops during late adolescence (15 or above) or adulthood. Treatment involves a combination of antipsychotic medication, psychological therapies and social support. Many people with psychosis go on to lead ordinary lives and for about 60 per cent of people, the symptoms disappear within 12 months from onset. However, for others, treatment is less straightforward and many do not respond to the initial antipsychotic treatment prescribed by their doctor. Early response to antipsychotic medication is known to be associated with better outcome and fewer subsequent episodes, and intervening early with effective treatments is therefore important.

The study was funded by the Wellcome Trust, the National Institute for Health Research Biomedical Research Centre (NIHR BRC) for Mental Health at the South London and Maudsley NHS Foundation Trust and King’s College London, and the Brain and Behaviour Research Foundation (NARSAD)

Ends

For up to the minute media alerts, follow us on Twitter or find out more on our Press Office blog

Notes to editors: The University of Nottinghamhas 42,000 students at award-winning campuses in the United Kingdom, China and Malaysia. It was ‘one of the first to embrace a truly international approach to higher education’, according to the Sunday Times University Guide 2013. It is also one of the most popular universities among graduate employers, one of the world’s greenest universities, and winner of the Times Higher Education Award for ‘Outstanding Contribution to Sustainable Development’. It is ranked in the UK's Top 10 and the World's Top 75 universities by the Shanghai Jiao Tong and the QS World Rankings.

More than 90 per cent of research at The University of Nottingham is of international quality, according to the most recent Research Assessment Exercise. The University aims to be recognised around the world for its signature contributions, especially in global food security, energy & sustainability, and health. The University won a Queen’s Anniversary Prize for Higher and Further Education for its research into global food security.

Impact: The Nottingham Campaign, its biggest ever fundraising campaign, will deliver the University’s vision to change lives, tackle global issues and shape the future. More news…

Story credits

More information is available from Charlotte Anscombe, Media Relations & Campaign Manager in the Communications Office at The University of Nottingham, on +44 (0)115 748 4417, charlotte.anscombe@nottingham.ac.uk

For interviews with the authors, or a copy of the paper, please contact Seil Collins, Press Officer, King’s College London, Institute of Psychiatry on +44 (0)207 848 5377 / +44 (0)7718 697176 or seil.collins@kcl.ac.uk

Paper reference: Palaniyappan, L. et al. ‘Cortical folding defects as markers of poor treatment response in first episode psychosis’ JAMA Psychiatry.

  CharlotteAnscombe

Charlotte Anscombe - Media Relations & Campaign Manager

Email: charlotte.anscombe@nottingham.ac.uk  Phone:+44 (0)115 74 84 417 Location: University Park

Additional resources

No additional resources for this article

Related articles

A new tool for brain research

Published Date
Tuesday 30th July 2013

Major national health award for brain tumour awareness campaign

Published Date
Wednesday 13th February 2013

Come on over and pick our brains

Published Date
Thursday 7th March 2013

Road-mapping the Asian brain

Published Date
Tuesday 3rd July 2012

Media Relations - External Relations

The University of Nottingham
C Floor, Pope Building (Room C4)
University Park
Nottingham, NG7 2RD

telephone: +44 (0) 115 951 5798
email: communications@nottingham.ac.uk